Literature DB >> 20406368

Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations.

A Arteaga1, N K Dhand, T McCann, C M Knottenbelt, A J Tebb, H Evans, P David Eckersall, I K Ramsey.   

Abstract

BACKGROUND: Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs.
OBJECTIVES: To assess whether control of hyperadrenocorticism (HAC) affects the concentrations of Hp, CRP, SAA, alkaline phosphatase (ALKP) and cholesterol, to determine whether these analytes can be used to assess control of HAC following trilostane treatment, and whether a combination of these tests offers a valid method of assessing disease control.
METHODS: Hp, CRP, SAA, ALKP and cholesterol were assessed in 11 dogs with spontaneous HAC before and after treatment with trilostane. Adequate control of HAC was defined as post-ACTH cortisol less than 150 nmol/l.
RESULTS: Significant reductions in Hp, ALKP, cholesterol and SAA (P<0.05) but not of CRP were found after control of HAC. Only Hp, cholesterol and ALKP were moderately informative (Se & Sp>0.7) of disease control when compared to adrenocorticotropin or corticotropin (ACTH) stimulation test. SAA and CRP were unhelpful (Se & Sp<0.7). The analysis of the combination of the analytes did not improve the correlation with ACTH stimulation test. CLINICAL RELEVANCE: Relying on these analytes does not provide additional information over ACTH stimulation test results when assessing control of HAC treated with trilostane.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406368     DOI: 10.1111/j.1748-5827.2009.00863.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  6 in total

1.  Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.

Authors:  C M Bonadio; E C Feldman; T A Cohen; P H Kass
Journal:  J Vet Intern Med       Date:  2014-05-26       Impact factor: 3.333

2.  Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.

Authors:  L Macfarlane; T Parkin; I Ramsey
Journal:  Vet Rec       Date:  2016-11-01       Impact factor: 2.695

3.  Effect of Intravenous or Perivascular Injection of Synthetic Adrenocorticotropic Hormone on Stimulation Test Results in Dogs.

Authors:  C M Johnson; P H Kass; T A Cohen; E C Feldman
Journal:  J Vet Intern Med       Date:  2017-04-13       Impact factor: 3.333

4.  Comparison of methods to monitor dogs with hypercortisolism treated with trilostane.

Authors:  Stefania Golinelli; Viviani de Marco; Rodolfo Oliveira Leal; Andrea Barbarossa; Camilla Aniballi; Elisa Maietti; Antonio Maria Tardo; Sara Galac; Federico Fracassi
Journal:  J Vet Intern Med       Date:  2021-10-21       Impact factor: 3.333

5.  Metabolomic Abnormalities in Serum from Untreated and Treated Dogs with Hyper- and Hypoadrenocorticism.

Authors:  Carolin Anna Imbery; Frank Dieterle; Claudia Ottka; Corinna Weber; Götz Schlotterbeck; Elisabeth Müller; Hannes Lohi; Urs Giger
Journal:  Metabolites       Date:  2022-04-09

6.  Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  Carolina Arenas Bermejo; Dolores Pérez Alenza; Paula García San José; Lidia Llauet; Laura Pérez-López; Carlos Melián; Edward C Feldman
Journal:  J Vet Intern Med       Date:  2020-06-13       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.